Thenalidine

Summary

Thenalidine (CHEMBL2105458) is an approved small molecule (ATC R06AX53); indicated across 2 conditions including allergic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R06AX53 (+2 more)
• Indications: 2 conditions
• Chemistry: 286.4 Da · C17H22N2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105458
Name	Thenalidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	27901
ATC	R06AX53, D04AA03, R06AX03
Molecular formula	C17H22N2S
Molecular weight	286.4
InChIKey	KLOHYVOVXOUKQI-UHFFFAOYSA-N

SMILES: CN1CCC(CC1)N(CC2=CC=CS2)C3=CC=CC=C3

IUPAC name: 1-methyl-N-phenyl-N-(thiophen-2-ylmethyl)piperidin-4-amine

Also known as: Tenalidina, Thenaldine, Thenalidine, Thenophenopiperidine, SID144206868, THENALIDINE, AS-716, thenalidine

Patent coverage: 341 distinct patent families (1,236 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Mu-type opioid receptor, D(3) dopamine receptor.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A2	6.4	AC50	398.7	nM	CHEMBL_ACT_25145855
CHRM2	6.16	AC50	699.2	nM	CHEMBL_ACT_25195591
CHRM1	6.12	AC50	761.6	nM	CHEMBL_ACT_25210088
SLC6A3	5.79	AC50	1608	nM	CHEMBL_ACT_25124814
KCNH2	5.54	AC50	2900	nM	CHEMBL_ACT_25117378
DRD3	5.35	AC50	4458	nM	CHEMBL_ACT_25194381
OPRM1	5.13	AC50	7422	nM	CHEMBL_ACT_25158030
ADRA2A	5.07	AC50	8451	nM	CHEMBL_ACT_25156284
HTR1A	5.06	AC50	8652	nM	CHEMBL_ACT_25164879

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	4	MONDO:0005271	MONDO:0005271

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).